I-APIS-Drug Peptide GLP-1 Semaglutide Umfanekiso obonakalayo

APIS-Iziyobisi Peptide GLP-1 Semaglutide

Inkcazelo emfutshane:

I-Semaglutide yi-GLP-1 entsha (i-glucagon-like peptide -1) i-analogue eyenziwe nguNovoNordisk, inkampani yaseDenmark.I-Semaglutide yifom yedosi yexesha elide esekelwe kwisiseko esisisiseko se-liraglutide, enempembelelo engcono ekuphatheni uhlobo lwe-2 yeswekile.I-Semaglutide ineempembelelo ezinenzuzo kumalungu amaninzi abalulekileyo, kuquka i-pancreas, intliziyo kunye nesibindi.

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iithegi zeMveliso

Malunga nale Nto

I-Semaglutide mhlawumbi i-agonist esebenzayo ye-GLP-1.
Okwangoku, amayeza aqhelekileyo okulahleka kwesisindo kwimarike abandakanya i-orlistat evela eRoche, i-liraglutide evela kwiNovo Nordisk kunye ne-semaglutide.

I-Wegovy, i-analogue ye-GLP-1 ye-Novo Nordisk, yavunywa yi-FDA kwi-2017 ukunyanga uhlobo lwe-2 yeswekile.NgoJuni ka-2021, i-FDA yamkele isalathiso sokuncipha kwe-Wegovy.

Ngo-2022, unyaka wokuqala opheleleyo wokuthengisa emva koluhlu lwe-Wegovy, i-Wegovy ifumene i-877 yezigidi zeedola kwiimpawu zokulahlekelwa kwesisindo.

Ngoluhlu lwe-semaglutide, ukulawulwa kwe-subcutaneous kanye ngeveki kuye kwaphucula kakhulu ukuthotyelwa kwezigulane, kwaye umphumo wokulahlekelwa kwesisindo ubonakala.Umphumo wokulahlekelwa kwesisindo kwiiveki ze-68 yi-12.5% ephezulu kune-placebo (14.9% vs 2.4%), kwaye ibe yimveliso yeenkwenkwezi kwimarike yokulahlekelwa kwesisindo ngexesha.

Kwikota yokuqala ka-2023, i-Wegovy izuze ingeniso ye-670 yezigidi zeedola zaseMelika, inyuka ngama-225% unyaka nonyaka.

Ukuvunywa kwesibonakaliso sokulahlekelwa kwesisindo se-semaglutide ikakhulu kusekelwe kwisifundo se-III esibizwa ngokuba yi-STEP.Uphononongo lwe-STEP luvavanya kakhulu umphumo wonyango we-injection subcutaneous ye-semaglutide 2.4mg kanye ngeveki xa kuthelekiswa ne-placebo kwizigulane ezigqithiseleyo.

Imveliso Dispaly

Kutheni Khetha Thina

Uphononongo lwe-STEP lubandakanya inani lezilingo, apho malunga ne-4,500 yabantu abadala abatyebileyo okanye abantu abadala abatyebileyo baqeshwe, kuquka:
I-STEP 1 isifundo (uncedo lwe-lifestyle intervention) luthelekisa ukhuseleko lweeveki ze-68 kunye nokusebenza kwe-injection subcutaneous ye-semaglutide 2.4mg kanye ngeveki kunye ne-placebo kwi-1961 obese okanye abantu abadala.

Iziphumo zibonise ukuba utshintsho oluqhelekileyo lobunzima bomzimba lwaluyi-14.9% kwiqela le-semaglutide kunye ne-2.4% kwiqela le-PBO.Xa kuthelekiswa ne-PBO, iziphumo zecala ze-semaglutide zesisu zixhaphake kakhulu, kodwa ininzi yazo idlula kwaye inokunciphisa ngaphandle kokumisa ngokusisigxina i-regimen yonyango okanye izigulane zihoxise kwisifundo.Uphando lwe-STEP1 lubonisa ukuba i-semaglutide inefuthe elihle lokulahlekelwa kwesisindo kwizigulane ezigqithiseleyo.

I-STEP 2 isifundo (izigulane ezigqithiseleyo kunye nohlobo lwe-2 yesifo sikashukela) zithelekisa ukhuseleko kunye nokusebenza kwe-injection subcutaneous ye-semaglutide i-2.4 mg kanye ngeveki kunye ne-placebo kunye ne-semaglutide i-1.0mg kwi-1210 abantu abadala okanye abantu abadala abagqithisileyo kwiiveki ze-68.

Iziphumo zibonise ukuba uqikelelo lobunzima bomzimba lwamaqela amathathu onyango lwatshintsha kakhulu, kunye -9.6% xa usebenzisa i-2.4 mg ye-semaglutide, -7% xa usebenzisa i-1.0mg ye-semaglutide, kunye -3.4% xa usebenzisa i-PBO.Uphando lwe-STEP2 lubonisa ukuba i-semaglutide iphinda ibonise umphumo omuhle wokulahlekelwa kwesisindo kwizigulane ezityebileyo kunye nohlobo lwe-2 yeswekile.

I-STEP 3 isifundo (i-adjuvant intensive behavioral therapy) ithelekisa umahluko weveki ye-68 ekukhuseleni kunye nokusebenza phakathi kwe-injection subcutaneous ye-semaglutide i-2.4 mg kanye ngeveki kunye ne-placebo edibeneyo kunye nonyango olunzulu lokuziphatha kwi-611 abantu abadala okanye abantu abadala.
Kwiiveki zokuqala ze-8 zophononongo, zonke izifundo zafumana ukutya okunekhalori ephantsi yokutya kunye nonyango olunzulu lokuziphatha kuyo yonke inkqubo yeeveki ze-68.Abathathi-nxaxheba bakwafuneka ukuba benze imizuzu eyi-100 yokuzivocavoca umzimba rhoqo ngeveki, kunye nokunyuka kwemizuzu engama-25 rhoqo kwiiveki ezine kunye nemizuzu engama-200 ngeveki.

Iziphumo zibonise ukuba ubunzima bomzimba wezigulane eziphathwe nge-semaglutide kunye nonyango lokuziphatha olunzulu lwehla nge-16% xa kuthelekiswa nesiseko, ngelixa iqela le-placebo lehla nge-5.7%.Ukususela kwidatha ye-STEP3, sinokubona umphumo wokuzivocavoca kunye nokutya ekulahlekeni kwesisindo, kodwa ngokuthakazelisayo, ukomeleza indlela yokuphila kubonakala kunempembelelo encinci ekomelezeni umphumo weziyobisi we-semaglutide.

Uvavanyo lokuthelekisa

(Ukuthelekiswa kwezinga lokulahlekelwa kwesisindo phakathi kweqela le-Semaglutide kunye neqela leDulaglutide)

Ichiza linokunyusa i-glucose metabolism ngokuvuselela iiseli ze-pancreatic β ukuba zikhuphe i-insulin;Kwaye inqanda iiseli ze-alpha ze-pancreatic ekukhupheni iglucagon, ngaloo ndlela inciphisa ukuzila kunye neswekile yegazi ye-postprandial.

(Ukuthelekiswa kobunzima bomzimba phakathi kweqela le-Semaglutide unyango kunye ne-placebo)

Xa kuthelekiswa ne-placebo, i-Semaglutide inokunciphisa umngcipheko wamanqaku okugqibela adibeneyo (ukufa kokuqala kwe-cardiovascular death, nonfatal myocardial infarction, unfatal stroke) nge-26%.Emva kweminyaka eyi-2 yonyango, i-Semaglutide inokunciphisa kakhulu umngcipheko we-stroke engapheliyo nge-39%, i-myocardial infarction engeyiyo i-26% kunye nokufa kwe-cardiovascular death nge-2%.Ukongezelela, kunokunciphisa ukutya ngokunciphisa ukutya kunye nokunciphisa ukucolwa kwesisu, kwaye ekugqibeleni kuncitshiswe amanqatha omzimba, okwenza kube lula ukunciphisa umzimba.

Kolu phononongo, kwafunyaniswa ukuba i-phentermine-topiramate kunye ne-GLP-1 receptor agonist zibonakaliswe njengezona ziyobisi zinciphisa ubunzima phakathi kwabantu abadala abatyebileyo nabatyebe kakhulu.

Ngaphambili:

Okulandelayo: Ikhathalogu peptide ELAMIPRETIDE/SS-31/MTP-131/ RX-31 Cardiolipin peroxidase inhibitor